| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $46.7M | +229.5% |
| SG&A Expense | $21.2M | +32.1% |
| Operating Income | -$67.9M | +17.2% |
| Income Tax | $0 | — |
| Net Income | -$59.9M | +19.0% |
| EPS (Basic) | -$0.88 | +42.5% |
| EPS (Diluted) | -$0.88 | +42.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $35.7M | -59.1% |
| Short-term Investments | $65.4M | +2.7% |
| Current Assets | $105.8M | -31.7% |
| Total Assets | $167.7M | -22.8% |
| Current Liabilities | $7.0M | +41.6% |
| Total Liabilities | $7.3M | +37.0% |
| Stockholders' Equity | $160.5M | -24.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$54.4M | -249.3% |
| Capital Expenditures | $186K | — |
| Investing Cash Flow | $2.8M | +102.3% |
| Financing Cash Flow | -$21K | -100.0% |
| Free Cash Flow | -$54.5M | -250.5% |